TANGYI HEALTHINA (SHENZHEN) MEDICAL BIOTECHNOLOGY CO

Overview

TANGYI HEALTHINA (SHENZHEN) MEDICAL BIOTECHNOLOGY CO is an active pharmaceutical ingredient (API) supplier with 4 active FDA Type II Drug Master Files, covering CELLS PRESERVATION SOLUTION; CRYOPRESERVATION SOLUTION; HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS DRUG SUBSTANCE; NATURAL KILLER CELLS DRUG SUBSTANCE.

API / Drug Master Files

TANGYI HEALTHINA (SHENZHEN) MEDICAL BIOTECHNOLOGY CO holds 4 active (4 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• CELLS PRESERVATION SOLUTIONActive2024-10-23
• CRYOPRESERVATION SOLUTIONActive2024-09-13
• NATURAL KILLER CELLS DRUG SUBSTANCEActive2024-07-30
• HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS DRUG SUBSTANCEActive2024-04-25

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to TANGYI HEALTHINA (SHENZHEN) MEDICAL BIOTECHNOLOGY CO in our records. PharmaTek screens the full directory against live FDA enforcement data.